Core Insights - CervoMed Inc. is advancing its clinical program for neflamapimod, targeting Dementia with Lewy Bodies (DLB), highlighted at the American Neurological Association conference [1][2] - The Phase 2b trial demonstrated a 74% risk reduction in clinically significant worsening of dementia symptoms compared to placebo in patients unlikely to have Alzheimer's disease co-pathology [2][4] - The company plans to initiate a Phase 3 trial in DLB patients, with alignment on trial design expected with the FDA in Q4 2025 [2] Company Overview - CervoMed is a clinical-stage company focused on treatments for age-related neurologic disorders, specifically developing neflamapimod, an investigational small molecule [5] - Neflamapimod targets synaptic dysfunction associated with neurodegenerative diseases, including DLB [5] Clinical Trial Details - The RewinD-LB Phase 2b trial was a randomized, double-blind, placebo-controlled study involving 159 DLB patients, assessing the efficacy of oral neflamapimod [4] - The trial was funded by a $21.3 million grant from the National Institutes of Health, with 43 sites across the U.S., U.K., and Netherlands [4] - The initial phase faced challenges in evaluating clinical activity due to issues with the drug formulation, but the Extension phase allowed for effective evaluation of the treatment [4]